Alderley Analytical
Liverpool
Product
Funding use
Sector
Amount
Fund
Summary
Alderely Analytical received an initial six-figure investment in July 2015 through the North West Biomedical Fund, which was initially managed by SPARK Impact and who have since operationally merged with River Capital.
The company’s growth from a startup to a major player in the bioanalytical services sector is a testament to the hard work of its founders and the potential of the region’s biomedical industry. Since 2014 the company has grown to employ around 60 highly qualified staff, have over 200 clients and have since relocated to specially designed laboratories.
With further growth projected, Alderley Analytical has established itself as a key player in supporting drug development programmes through discovery, pre-clinical safety testing, and clinical development and due to its success has yielded substantial returns, with the fund expecting to receive more than four times its initial funding following its acquisition by Synexa Life Sciences, a Dutch-based company backed by major European healthcare investor Gilde Healthcare.
“As we enter this new phase with Synexa Life Sciences, we’re grateful for the early support from River Capital. Their investment allowed us to build a company that delivers high-quality, bespoke bioanalytical services to pharmaceutical, biotech, and CRO clients worldwide.”
